Mechanism Capital’s Andrew Kang said DeSci protocols will likely change their existing models before evolving into more market-ready products.

DeSci, Healthcare, Andrew Kang, Mechanism Capital, BIO Protocol, Pump Science, GLP1, OriginTrailRead More

You might also be interested in reading Onchain Data Flags Suspicious Bets on Polymarket and Hyperliquid Ahead of Trump’s Iran Deal.